Free Trial
NASDAQ:ONC

Beigene 5/7/2025 Earnings Report

Beigene logo
$237.38 +5.13 (+2.21%)
As of 03:52 PM Eastern

Beigene EPS Results

Actual EPS
$1.22
Consensus EPS
-$0.71
Beat/Miss
Beat by +$1.93
One Year Ago EPS
N/A

Beigene Revenue Results

Actual Revenue
$1.12 billion
Expected Revenue
$1.12 billion
Beat/Miss
Missed by -$7.30 million
YoY Revenue Growth
N/A

Beigene Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Beigene Earnings Headlines

Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
BeiGene Q1 2025 Earnings Preview
See More Beigene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beigene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beigene and other key companies, straight to your email.

About Beigene

Beigene (NASDAQ:ONC) Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

View Beigene Profile

More Earnings Resources from MarketBeat